206 related articles for article (PubMed ID: 12091331)
1. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.
Aricò M; Valsecchi MG; Conter V; Rizzari C; Pession A; Messina C; Barisone E; Poggi V; De Rossi G; Locatelli F; Micalizzi MC; Basso G; Masera G
Blood; 2002 Jul; 100(2):420-6. PubMed ID: 12091331
[TBL] [Abstract][Full Text] [Related]
2. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
[TBL] [Abstract][Full Text] [Related]
3. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
4. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
Conter V; Schrappe M; Aricó M; Reiter A; Rizzari C; Dördelmann M; Valsecchi MG; Zimmermann M; Ludwig WD; Basso G; Masera G; Riehm H
J Clin Oncol; 1997 Aug; 15(8):2786-91. PubMed ID: 9256120
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
[TBL] [Abstract][Full Text] [Related]
6. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
[TBL] [Abstract][Full Text] [Related]
7. Risk-directed therapy for childhood acute lymphoblastic leukemia. Results of the Associazione Italiana Ematologia Oncologia Pediatrica '82 studies.
Vecchi V; Aricò M; Basso G; Ceci A; Madon E; Mandelli F; Masera G; Massimo L; Pession A; Zanesco L
Cancer; 1993 Oct; 72(8):2517-24. PubMed ID: 8402470
[TBL] [Abstract][Full Text] [Related]
8. [The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial].
Zdráhalová K; Štěrba J; Domanský J; Blažek B; Ptoszková H; Mihál V; Novák Z; Hak J; Procházková D; Černá Z; Timr P; Jabali Y; Sedláček P; Smíšek P; Zemanová Z; Jarošová M; Houdková A; Mejstříková E; Hrušák O; Zuna J; Janotová I; Trka J; Starý J
Cas Lek Cesk; 2015; 154(2):79-89. PubMed ID: 25994910
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.
Steinherz PG; Gaynon PS; Breneman JC; Cherlow JM; Grossman NJ; Kersey JH; Johnstone HS; Sather HN; Trigg ME; Uckun FM; Bleyer WA
Cancer; 1998 Feb; 82(3):600-12. PubMed ID: 9452280
[TBL] [Abstract][Full Text] [Related]
10. Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
Grenzebach J; Schrappe M; Ludwig WD; Parwaresch R; Zimmermann M; Gadner H; Riehm H; Reiter A;
Ann Hematol; 2001; 80 Suppl 3():B73-6. PubMed ID: 11757713
[TBL] [Abstract][Full Text] [Related]
11. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
Aricò M; Basso G; Mandelli F; Rizzari C; Colella R; Barisone E; Zanesco L; Rondelli R; Pession A; Masera G
Cancer; 1995 Apr; 75(7):1684-93. PubMed ID: 8826928
[TBL] [Abstract][Full Text] [Related]
12. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
Rizzari C; Valsecchi MG; Aricò M; Conter V; Testi A; Barisone E; Casale F; Lo Nigro L; Rondelli R; Basso G; Santoro N; Masera G;
J Clin Oncol; 2001 Mar; 19(5):1297-303. PubMed ID: 11230471
[TBL] [Abstract][Full Text] [Related]
13. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
14. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Möricke A; Zimmermann M; Valsecchi MG; Stanulla M; Biondi A; Mann G; Locatelli F; Cazzaniga G; Niggli F; Aricò M; Bartram CR; Attarbaschi A; Silvestri D; Beier R; Basso G; Ratei R; Kulozik AE; Lo Nigro L; Kremens B; Greiner J; Parasole R; Harbott J; Caruso R; von Stackelberg A; Barisone E; Rössig C; Conter V; Schrappe M
Blood; 2016 Apr; 127(17):2101-12. PubMed ID: 26888258
[TBL] [Abstract][Full Text] [Related]
16. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
[TBL] [Abstract][Full Text] [Related]
17. Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.
Jung M; Schieck M; Hofmann W; Tauscher M; Lentes J; Bergmann A; Stelter M; Möricke A; Alten J; Schlegelberger B; Schrappe M; Zimmermann M; Stanulla M; Cario G; Steinemann D
Genes Chromosomes Cancer; 2020 Nov; 59(11):667-671. PubMed ID: 32592278
[TBL] [Abstract][Full Text] [Related]
18. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.
Schrappe M; Aricò M; Harbott J; Biondi A; Zimmermann M; Conter V; Reiter A; Valsecchi MG; Gadner H; Basso G; Bartram CR; Lampert F; Riehm H; Masera G
Blood; 1998 Oct; 92(8):2730-41. PubMed ID: 9763557
[TBL] [Abstract][Full Text] [Related]
19. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
[TBL] [Abstract][Full Text] [Related]
20. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
